FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3213896164> ?p ?o ?g. }

• W3213896164 endingPage "3775" @default.
• W3213896164 startingPage "3775" @default.
• W3213896164 abstract "Abstract Background: Heavily pretreated relapsed and refractory multiple myeloma (RR MM) constitutes a specific and unmet medical need. Median survival ranges from as little as 6 to 9 months, and responses to treatment are characteristically short (Richardson et al. 2007). Belantamab Mafodotin (BM), a novel anti-BCMA antibody conjugated to microtubule-disrupting agent monomethyl auristatin F, showed single-agent activity in the phase 1 DREAMM-1 and phase 2 DREAMM-2 studies in heavily pre-treated patients with RRMM (Lonial et al, 2019 & 2021). We aim to assess efficacy and safety of BM treatment administered via the expanded access compassionate care program for triple class MMRR patients in the region of Madrid (Spain). Methods: An observational, retrospective and multicenter study has been performed including all patients who received at least one dose of BM under the expanded access program in the region of Madrid (Spain) from Nov 2019 to Jun 2021. Hematology centers provided data from the medical records and entered them in a case report form distributed to the sites. Primary endpoint was overall response rate (ORR). Secondary endpoints were progression free survival (PFS), overall survival (OS) and the incidence of treatment emergent adverse events (TEAEs), with a major focus on ocular and hematologic toxicity. Results: A total of 33 patients (pts), from 14 different centers, were included from February 2020 till May 2021. Median age was 70 (46-79) years. 55% of the pts were women. Median time from diagnosis was 71 (10-858) months. 30.3% were high-risk cytogenetic features. Median of prior therapy lines was 5 (3-8) and at least 88% of the pts were triple class refractory. The median number of BM doses per patient was 3 (1-16) and the median follow-up was 11 months (95%CI 6.34-15.66). ORR was 42.2%, and 18.2% achieved ≥VGPR. Median PFS was 3 months (95%CI 0.92-5.08). Median PFS for patients who achieved ≥PR was 11 months (HR 0,26; 95% CI 0,10-0,68). No significant differences were found in PFS according to age, cytogenetic risk and prior therapy lines. OS was 424 days (95% CI 107-740). The incidence of non-hematological TEAEs was 57.6% and the most common of which was ocular toxicity (45.5%). The incidence of ≥G3 non-hematological TEAEs was 30.3%. 51.5% of the pts were diagnosed of keratopathy and 21.2% was ≥G3. 30.3% of the pts showed a reduced visual acuity, but this event was resolved in 92.9% of the pts. The most common symptoms were blurry vision (30.3%, n=10) and dry eye (24.2%, n=8). The incidence of ≥G3 hematological TEAEs was 18.2% and thrombocytopenia was the most frequent (21.2%). Dose reductions of BM were required in 30.3% of the pts and delayed in 36.4% due to TEAEs. Main causes for treatment discontinuation (81%, n=27) were disease progression (54.5%, n=18), toxicity (15.2%, n=5), death (6.1%, n=3) and due to patient's decision (3%, n=1). Conclusion: Compassionate use of BM in heavily pretreated RR MM pts showed a relevant anti-myeloma activity with a manageable safety profile.These results are similar to those observed in the DREAMM-1 and DREAMM-2 clinical trials. Disclosures No relevant conflicts of interest to declare." @default.
• W3213896164 created "2021-11-22" @default.
• W3213896164 creator A5003687791 @default.
• W3213896164 creator A5008387712 @default.
• W3213896164 creator A5013916379 @default.
• W3213896164 creator A5015087664 @default.
• W3213896164 creator A5020921101 @default.
• W3213896164 creator A5023790937 @default.
• W3213896164 creator A5027318437 @default.
• W3213896164 creator A5028097465 @default.
• W3213896164 creator A5034182883 @default.
• W3213896164 creator A5034430204 @default.
• W3213896164 creator A5040180604 @default.
• W3213896164 creator A5040895399 @default.
• W3213896164 creator A5053367647 @default.
• W3213896164 creator A5054061312 @default.
• W3213896164 creator A5054913221 @default.
• W3213896164 creator A5057553435 @default.
• W3213896164 creator A5064552707 @default.
• W3213896164 creator A5065757435 @default.
• W3213896164 creator A5077975123 @default.
• W3213896164 creator A5086096771 @default.
• W3213896164 creator A5086848835 @default.
• W3213896164 date "2021-11-05" @default.
• W3213896164 modified "2023-10-18" @default.
• W3213896164 title "Compassionate Use of Belantamab Mafodotin for Treatment of Patients with Relapsed/Refractory Multiple Myeloma Heavily Treated. Spanish Experience" @default.
• W3213896164 doi "https://doi.org/10.1182/blood-2021-151267" @default.
• W3213896164 hasPublicationYear "2021" @default.
• W3213896164 type Work @default.
• W3213896164 sameAs 3213896164 @default.
• W3213896164 citedByCount "3" @default.
• W3213896164 countsByYear W32138961642022 @default.
• W3213896164 countsByYear W32138961642023 @default.
• W3213896164 crossrefType "journal-article" @default.
• W3213896164 hasAuthorship W3213896164A5003687791 @default.
• W3213896164 hasAuthorship W3213896164A5008387712 @default.
• W3213896164 hasAuthorship W3213896164A5013916379 @default.
• W3213896164 hasAuthorship W3213896164A5015087664 @default.
• W3213896164 hasAuthorship W3213896164A5020921101 @default.
• W3213896164 hasAuthorship W3213896164A5023790937 @default.
• W3213896164 hasAuthorship W3213896164A5027318437 @default.
• W3213896164 hasAuthorship W3213896164A5028097465 @default.
• W3213896164 hasAuthorship W3213896164A5034182883 @default.
• W3213896164 hasAuthorship W3213896164A5034430204 @default.
• W3213896164 hasAuthorship W3213896164A5040180604 @default.
• W3213896164 hasAuthorship W3213896164A5040895399 @default.
• W3213896164 hasAuthorship W3213896164A5053367647 @default.
• W3213896164 hasAuthorship W3213896164A5054061312 @default.
• W3213896164 hasAuthorship W3213896164A5054913221 @default.
• W3213896164 hasAuthorship W3213896164A5057553435 @default.
• W3213896164 hasAuthorship W3213896164A5064552707 @default.
• W3213896164 hasAuthorship W3213896164A5065757435 @default.
• W3213896164 hasAuthorship W3213896164A5077975123 @default.
• W3213896164 hasAuthorship W3213896164A5086096771 @default.
• W3213896164 hasAuthorship W3213896164A5086848835 @default.
• W3213896164 hasBestOaLocation W32138961641 @default.
• W3213896164 hasConcept C120665830 @default.
• W3213896164 hasConcept C121332964 @default.
• W3213896164 hasConcept C126322002 @default.
• W3213896164 hasConcept C141071460 @default.
• W3213896164 hasConcept C142424586 @default.
• W3213896164 hasConcept C197934379 @default.
• W3213896164 hasConcept C203092338 @default.
• W3213896164 hasConcept C2775832928 @default.
• W3213896164 hasConcept C2776364478 @default.
• W3213896164 hasConcept C2780739268 @default.
• W3213896164 hasConcept C3019894029 @default.
• W3213896164 hasConcept C535046627 @default.
• W3213896164 hasConcept C61511704 @default.
• W3213896164 hasConcept C71924100 @default.
• W3213896164 hasConcept C87355193 @default.
• W3213896164 hasConceptScore W3213896164C120665830 @default.
• W3213896164 hasConceptScore W3213896164C121332964 @default.
• W3213896164 hasConceptScore W3213896164C126322002 @default.
• W3213896164 hasConceptScore W3213896164C141071460 @default.
• W3213896164 hasConceptScore W3213896164C142424586 @default.
• W3213896164 hasConceptScore W3213896164C197934379 @default.
• W3213896164 hasConceptScore W3213896164C203092338 @default.
• W3213896164 hasConceptScore W3213896164C2775832928 @default.
• W3213896164 hasConceptScore W3213896164C2776364478 @default.
• W3213896164 hasConceptScore W3213896164C2780739268 @default.
• W3213896164 hasConceptScore W3213896164C3019894029 @default.
• W3213896164 hasConceptScore W3213896164C535046627 @default.
• W3213896164 hasConceptScore W3213896164C61511704 @default.
• W3213896164 hasConceptScore W3213896164C71924100 @default.
• W3213896164 hasConceptScore W3213896164C87355193 @default.
• W3213896164 hasIssue "Supplement 1" @default.
• W3213896164 hasLocation W32138961641 @default.
• W3213896164 hasOpenAccess W3213896164 @default.
• W3213896164 hasPrimaryLocation W32138961641 @default.
• W3213896164 hasRelatedWork W1985923042 @default.
• W3213896164 hasRelatedWork W2528057197 @default.
• W3213896164 hasRelatedWork W2753152865 @default.
• W3213896164 hasRelatedWork W2894779831 @default.
• W3213896164 hasRelatedWork W2909807743 @default.
• W3213896164 hasRelatedWork W3028908409 @default.
• W3213896164 hasRelatedWork W4283376564 @default.
• W3213896164 hasRelatedWork W4285091731 @default.

• next